Objectives: The present study was undertaken to investigate the antidepressant potential of trans-anethole in unstressed and stressed male mice. Methods: Swiss albino male mice were exposed to chronic unpredictable mild stress for 21 successive days. Simultaneously, trans-anethole (12.5 mg/kg, 25 mg/kg, and 50 mg/kg) and fluoxetine (20 mg/kg) per se were administered for 21 successive days to separate groups of unstressed and stressed mice. The effect of drugs on depressive-like behavior of mice was tested by tail suspension test (TST) and sucrose preference test. Results: Trans-anethole (25 mg/kg) and fluoxetine significantly decreased the immobility period of unstressed and stressed mice in TST as compared to their respective control. The...
International audienceThe novel antidepressant agomelatine behaves as an agonist at melatonergic MT(...
International audienceThe novel antidepressant agomelatine behaves as an agonist at melatonergic MT(...
International audienceThe novel antidepressant agomelatine behaves as an agonist at melatonergic MT(...
The present study has been exposed that administration of APDM could normalize behavioral, biogenic ...
The aim of this study was to investigate the antidepressant effects of grape seed oil in male mice (...
Context: Anxiety is a common psychological disorder, often occurring in combination with depression,...
Chronic stress is considered a vulnerability factor for depression. A key symptom is anhedonia; a re...
Background: Depression is the most common psychiatric illness that involves mood disturbances affect...
Depression is a prevalent mental illness. According to estimates, 5 percent of adults worldwide expe...
<p>When social stress was imposed during treatment, fluoxetine-treated mice showed a faster and more...
Jie Yu Chu Fan capsule (JYCF) is a new compounded Chinese herbal medicine for the treatment of depre...
Evidence show that gamma-aminobutyric acid (GABA) receptors are involved in depression, so the aim o...
International audienceThe novel antidepressant agomelatine behaves as an agonist at melatonergic MT(...
International audienceThe novel antidepressant agomelatine behaves as an agonist at melatonergic MT(...
International audienceThe novel antidepressant agomelatine behaves as an agonist at melatonergic MT(...
International audienceThe novel antidepressant agomelatine behaves as an agonist at melatonergic MT(...
International audienceThe novel antidepressant agomelatine behaves as an agonist at melatonergic MT(...
International audienceThe novel antidepressant agomelatine behaves as an agonist at melatonergic MT(...
The present study has been exposed that administration of APDM could normalize behavioral, biogenic ...
The aim of this study was to investigate the antidepressant effects of grape seed oil in male mice (...
Context: Anxiety is a common psychological disorder, often occurring in combination with depression,...
Chronic stress is considered a vulnerability factor for depression. A key symptom is anhedonia; a re...
Background: Depression is the most common psychiatric illness that involves mood disturbances affect...
Depression is a prevalent mental illness. According to estimates, 5 percent of adults worldwide expe...
<p>When social stress was imposed during treatment, fluoxetine-treated mice showed a faster and more...
Jie Yu Chu Fan capsule (JYCF) is a new compounded Chinese herbal medicine for the treatment of depre...
Evidence show that gamma-aminobutyric acid (GABA) receptors are involved in depression, so the aim o...
International audienceThe novel antidepressant agomelatine behaves as an agonist at melatonergic MT(...
International audienceThe novel antidepressant agomelatine behaves as an agonist at melatonergic MT(...
International audienceThe novel antidepressant agomelatine behaves as an agonist at melatonergic MT(...
International audienceThe novel antidepressant agomelatine behaves as an agonist at melatonergic MT(...
International audienceThe novel antidepressant agomelatine behaves as an agonist at melatonergic MT(...
International audienceThe novel antidepressant agomelatine behaves as an agonist at melatonergic MT(...